Table 1.

Demographic characteristics and clinical features of the post-surgical GBS and general GBS patients examined in this study

Parameters	GBS without recent surgery (n = 956)	GBS after surgery (n = 45)	Two-tailed P-value
Patient age (mean, y)	51.37 ± 15.85	53.93 ± 12.86	0.285
Male, n (%)	575 (60.1)	26 (57.8)	0.751
Diabetes mellitus, n (%)	72 (7.5)	4 (8.9)	0.962
Hypertension, n (%)	241 (25.2)	11 (24.4)	0.908
Initial symptoms, n (%)
Motor weakness	729 (76.3)	36 (80.0)	0.563
Sensory change	402 (42.1)	12 (25.2)	0.041
HFGS score upon admission, n (%)
≥ 3	608 (63.6)	37 (82.2)	0.011
< 3	348 (36.4)	8 (17.8)
HFGS score at nadir, n (%)
≥ 3	692 (72.4)	41 (91.1)	0.006
< 3	264 (27.6)	4 (8.9)
Hospital stay (d)	15 (11–20)	21 (14–26)	0.000
HFGS score at discharge (g)	2 (1–3)	3 (2–4)	0.001
Mechanical ventilation (MV), n (%)	91 (9.5)	4 (8.9)	1.000
Deaths during hospital stay, n (%)	6 (0.6)	1 (2.2)	0.276
Lumbar puncture	757	31
Mean protein concentration (g/L)	1.18 ± 0.86	0.99 ± 0.71	0.346
Albumin-cytologic dissociations, n (%)	611 (80.7)	23 (74.2)	0.370
Electrodiagnostic subtypes, n (%)	691	29
AIDP	339 (49.1)	12 (41.4)	0.418
AMAN	98 (14.2)	11 (37.9)	0.001
AMSAN	21	2	0.236
Treatment, n (%)
IVIg	407 (42.6)	18 (40.0)	0.733
Plasmapheresis	41 (4.3)	1 (2.2)	0.768

AIDP acute inflammatory demyelinating polyneuropathy, AMAN acute motor axonal neuropathy, AMSAN acute motor sensory axonal neuropathy, GBS Guillain-Barré syndrome, HFGS Hughes Functional Grading Scale, IVIg intravenous immunoglobulin. Statistically significant results are shown in bold